What is the clinical evidence from this study?

Study design: Review. Population: Hypertension. Intervention: Telmisartan.

What question did this study set out to answer?

To review the pharmacological properties of telmisartan in hypertension management and assess evidence for its broader organ-protective and metabolic actions.

November 11, 2011Expert Opinion on Pharmacotherapy

Telmisartan: just an antihypertensive agent? A literature review

View Full Paper

Ask AI

Bookmark

Key result

Telmisartan provides sustained blood pressure reduction and exhibits unique cardiovascular protective properties, including PPAR-γ modulation, that extend beyond its antihypertensive effects.

Design

Review

Authors

MDMaurizio DestroInternational Hospital Kampala FCFrancesca CagnoniInternational Hospital Kampala GDGiuseppina DogniniAzienda Ospedaliera Treviglio

Discussion

Member takes

Implication

Telmisartan's organ-protective signals beyond BP control merit targeted trials; leaves open any practice shift pending confirmatory RCTs.

Key Points

To review the pharmacological properties of telmisartan in hypertension management and assess evidence for its broader organ-protective and metabolic actions.
Synthesized pharmacologic and clinical trial data evaluating telmisartan's 24-hour antihypertensive efficacy.
Assessed clinical outcomes from landmark studies, including the ONTARGET trial, regarding cardiovascular and renal endpoints.
Telmisartan features the longest half-life among all angiotensin II receptor blockers, delivering sustained 24-hour blood pressure reduction along with reductions in left ventricular hypertrophy, arterial stiffness, and atrial fibrillation recurrence.
Clinical evidence from the ONTARGET trial demonstrates cardiovascular protection comparable to ramipril but with superior patient tolerability.
Telmisartan modulates peroxisome proliferator-activated receptor-gamma (PPAR-γ), promoting anti-inflammatory, anti-atherosclerotic, and insulin-sensitizing actions against target end-organ damage.

Structured PICO

Intervention

Telmisartan

Telmisartan is an ARB with unique pharmacological properties, including PPAR-gamma modulation, that offer cardiovascular and end-organ protection beyond blood pressure control.

Cite This Study

Destro et al. (2011) conducted a review in Hypertension. Telmisartan was evaluated. Telmisartan provides sustained blood pressure reduction and exhibits unique cardiovascular protective properties, including PPAR-γ modulation, that extend beyond its antihypertensive effects.

synapsesocial.com/papers/6a6bc7eb6f523709a024ceea https://doi.org/10.1517/14656566.2011.632367

Topics

Hypertension management Persistent AF management Atrial fibrillation

View Full Paper

Ask AI

Bookmark

Telmisartan: just an antihypertensive agent? A literature review

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Telmisartan: just an antihypertensive agent? A literature review

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider